Sun Pharma and Zydus Join Forces to Co-Market Innovative Anemia Drug for CKD in India

30 Oct 2023 , 12:38 PM

Sun Pharmaceutical Industries and Zydus Lifesciences announce a licensing agreement to co-market the innovative drug, Desidustat, in India, for treating anemia associated with Chronic Kidney Disease (CKD).

Zydus grants Sun Pharma semi-exclusive rights to co-market the product in India, with Sun Pharma marketing the drug as RYTSTAT®.

Zydus initially launched the drug as Oxemia™ in 2022 and will continue to market it. Zydus will receive upfront licensing income and may receive milestone income based on predefined achievements.

Kirti Ganorkar, CEO – India Business, Sun Pharma, highlights the partnership’s role in strengthening their nephrology portfolio and improving the quality of life for CKD patients in India.

For feedback and suggestions, write to us at [e-mail]